Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic